|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 他司鲁泰>> 市场分析报告 |
他司鲁泰市场分析报告 |
|
Taspoglutide (CAS 275371-94-3) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Global Market Report of Taspoglutide (CAS 275371-94-3) December 2024 Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012 This report “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012” published in March 2012 provides a compilation of business, commercial, clinical and scientific information about GLP-1 receptor agonists. A ... Global Diabetes Market Trends & Future Forecast - Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1 ... (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future ... : Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide; ; Data Sources ; ; Information and data ... China Diabetes Market Report & Outlook For 2010-2015 As the second largest economy of the world, China enjoys pink of health but its affluence is giving rise to another sickness- a rapid increase in a life-style disease called diabetes. With the Chinese Population getting richer, fatter and less mobile, ... Indian Diabetes Market Report & Outlook For 2010-2015 With around 51 Million diabetes patients, India promises to be amongst the most lucrative diabetes markets in the world. In 2009, the total sales of Insulin and Non-Insulin Anti-diabetics reached US$ 424 Million. Although, this represents just a fraction ... Conference Intelligence Dossier: EASD Annual Meeting 2009 The numbers are staggering: More than 200 million people around the world now suffer from diabetes and its major complications. According to the World Health Organization, that figure is expected to surpass 366 million by 2030—even if obesity rates remain ... The State of Roche ... -1 trial, the first five studies on taspoglutide and the BTT-1023 trial ... Accutane Dacetuzumab RG7128 for hepatitis C Taspoglutide Xeloda BTT-1023 for rheumatoid ... Amylin Take Over Battle - A 25 -50% upside is very much there ... launch); A waning competition - The failure of taspoglutide, delay in development of weekly versions by Novo ... |